APA (7th ed.) Citation

CMJ, W., B, N., J, A., K, A., A, A., C, A., . . . ME, S. (2024). Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia bulletin, 50(3), 496. https://doi.org/10.1093/schbul/sbae011

Chicago Style (17th ed.) Citation

CMJ, Wannan, et al. "Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis." Schizophrenia Bulletin 50, no. 3 (2024): 496. https://doi.org/10.1093/schbul/sbae011.

MLA (9th ed.) Citation

CMJ, Wannan, et al. "Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis." Schizophrenia Bulletin, vol. 50, no. 3, 2024, p. 496, https://doi.org/10.1093/schbul/sbae011.